Genmab As (GNMSF) Cut to Sell at Zacks Investment Research

Genmab As (OTCMKTS:GNMSF) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a note issued to investors on Tuesday, January 9th.

According to Zacks, “Genmab A/S is a biotechnology company that creates and develops human antibodies for the treatment of life-threatening and debilitating diseases. Genmab has numerous products in development to treat cancer, infectious disease, rheumatoid arthritis and other inflammatory conditions, and intends to continue assembling a broad portfolio of new therapeutic products. In addition, Genmab has developed UniBody, a new proprietary technology that creates a stable, smaller antibody format. Genmab has operations in Europe and the US. “

Separately, JPMorgan Chase & Co. downgraded Genmab As from an “overweight” rating to a “neutral” rating in a report on Friday, October 6th.

Shares of Genmab As (OTCMKTS GNMSF) traded down $3.04 during mid-day trading on Tuesday, hitting $188.00. The company’s stock had a trading volume of 1,762 shares, compared to its average volume of 1,510. Genmab As has a 52-week low of $163.00 and a 52-week high of $239.75. The firm has a market cap of $11,690.00 and a P/E ratio of 66.10.

WARNING: This report was originally reported by BBNS and is the property of of BBNS. If you are reading this report on another publication, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The original version of this report can be read at https://baseballnewssource.com/markets/genmab-as-gnmsf-downgraded-by-zacks-investment-research-to-sell/1823414.html.

About Genmab As

Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer in Denmark and internationally. The company markets Arzerra, a human monoclonal antibody for the treatment of chronic lymphocytic leukemia (CCL); and DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM).

Get a free copy of the Zacks research report on Genmab As (GNMSF)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Genmab As Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab As and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Rumor: Milwaukee Brewers Offer Yu Darvish Contract
Rumor: Milwaukee Brewers Offer Yu Darvish Contract
Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Houston Astros Add Starter to Rotation
Houston Astros Add Starter to Rotation
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Justin Morneau Former Star With Twins and AL MVP Retires
Justin Morneau Former Star With Twins and AL MVP Retires


Leave a Reply

 
© 2006-2018 BBNS.